Products & Portfolio (26)
6 discontinued products not shown
APIXABAN
apixaban
Pre-Launch
ORAL · TABLET
FXa. It does not require antithrombin III for antithrombotic activity. Apixaban inhibits free and clot-bound FXa, and prothrombinase activity. Apixaban has no direct effect on platelet aggregation, but indirectly inhibits platelet aggregation induced by thrombin. By inhibiting FXa, apixaban decreases thrombin generation and thrombus development.
deep vein thrombosis (DVT)which may lead to pulmonary embolism (PE)knee replacement surgery+10 more
ARIPIPRAZOLE
aripiprazole
Post-LOE
SMORAL · TABLET
unclear. However, the efficacy of aripiprazole in the listed indications could be mediated through a combination of partial agonist activity at D 2 and 5-HT 1A receptors and antagonist activity at 5-HT 2A receptors.
Tourette's Disorder Aripiprazole is an atypical antipsychoticTourette's disorder (14Schizophrenia
2023
30
AZITHROMYCIN
azithromycin
Post-LOE
ORAL · TABLET
drug. [see ]
development of drug-resistant bacteriamaintain the effectiveness of azithromycinother antibacterial drugs+2 more
2018
30
AZITHROMYCIN
azithromycin
Post-LOE
ORAL · TABLET
drug. [see ]
development of drug-resistant bacteriamaintain the effectiveness of azithromycinother antibacterial drugs+2 more
2018
30
AZITHROMYCIN
azithromycin
Post-LOE
ORAL · TABLET
drug. [see Microbiology ()]
development of drug-resistant bacteriamaintain the effectiveness of azithromycin for oral suspensionother antibacterial drugs+4 more
2018
30
BRIVARACETAM
brivaracetam
Post-LOE
ORAL · TABLET
Epoxide Hydrolase Inhibitors
partial-onset seizures in patients 1 month of ageolder
2022
30
CLARITHROMYCIN
clarithromycin
Post-LOE
ORAL · TABLET, EXTENDED RELEASE
Cytochrome P450 3A4 Inhibitors
mild to moderate infections caused by susceptible isolates due to Haemophilus influenzaeMoraxella catarrhalisUsage ]+8 more
2018
30
DULOXETINE HYDROCHLORIDE
duloxetine hydrochloride
Post-LOE
ORAL · CAPSULE, DELAYED REL PELLETS
antidepressant, central pain inhibitory and anxiolytic actions of duloxetine in humans are unknown, these actions are believed to be related to its potentiation of serotonergic and noradrenergic activity in the CNS.
the following conditions: Major depressive disorder (MDD) in adults ( ) Generalized anxiety disorder (GAD) in adultsolder ( ) Diabetic peripheral neuropathic pain (DPNP) in adults ( ) Fibromyalgia (FM) in adultsolder ( ) Chronic musculoskeletal pain in adults ( )+1 more
2021
30
ENTACAPONE
entacapone
Post-LOE
ORAL · TABLET
Catechol O-Methyltransferase Inhibitors
Parkinson's disease (see )Parkinson's disease
2018
30
FEBUXOSTAT
febuxostat
Post-LOE
SMORAL · TABLET
Xanthine Oxidase Inhibitors
2020
30
LINAGLIPTIN
linagliptin
Post-LOE
SMORAL · TABLET
Dipeptidyl Peptidase 4 Inhibitors
2021
30
LINAGLIPTIN AND METFORMIN HYDROCHLORIDE
linagliptin; metformin hydrochloride
Post-LOE
ORAL · TABLET
2021
30
Open Jobs (0)
No open positions listed yet.
Interview Prep Quick Facts
Portfolio: 32 approved products
Top TAs: Cardiovascular, Infectious Diseases, Neurology
H-1B (2023): 1 approval
Portfolio Health
Pre-Launch3 (9%)
Post-LOE29 (91%)
32 total products
Therapeutic Area Focus
Cardiovascular
5 marketed
Infectious Diseases
4 marketed
Neurology
4 marketed
Metabolic Diseases
2 marketed
Respiratory
1 marketed
Marketed
Pipeline
Visa Sponsorship
Sponsors Work Visas
H-1B Petitions (FY2023)
1
Approved
0
Denied
100%
Rate
Source: USCIS H-1B Employer Data Hub